Value of transjugular intrahepatic portosystemic shunt in the prevention of esophageal variceal rebleeding in patients with portal vein thrombosis after splenectomy

Zhaopeng LI; Guangchuan WANG; Chunqing ZHANG

doi:10.3969/j.issn.1001-5256.2021.06.023

Volume 37 Issue 6

Jun. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(6): 1331-1335

PDF( 3009 KB)

Value of transjugular intrahepatic portosystemic shunt in the prevention of esophageal variceal rebleeding in patients with portal vein thrombosis after splenectomy

DOI: 10.3969/j.issn.1001-5256.2021.06.023

1.
Department of Interventional Radiography, Qingdao Municipal Hospital, Qingdao, Shandong 266011, China
2.
Department of Gastroenterology, Shandong Provincial Hospital, Jinan 250021, China

Received Date: 2020-10-28
Accepted Date: 2020-12-16
Published Date: 2021-06-20

Abstract

Abstract

Objective To investigate the technical success rate and outcome of transjugular intrahepatic portosystemic shunt (TIPS) in preventing esophageal variceal rebleeding in patients with portal vein thrombosis (PVT) after splenectomy. Methods A retrospective analysis was performed for the clinical data of 46 patients with PVT after splenectomy who were admitted to Shandong Provincial Hospital from December 2009 to January 2017 and underwent TIPS to prevent esophageal variceal rebleeding. According to the success or failure of TIPS, the patients were divided into TIPS success group with 38 patients and TIPS failure group with 8 patients. The two groups were compared in terms of postoperative variceal rebleeding, stent dysfunction, hepatic encephalopathy (HE), and survival. The paired t-test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier curve was used to analyze variceal rebleeding-free rate, stent patency rate, HE-free rate, and survival rate, and the log-rank test was used for comparison of cumulative rebleeding-free rate and cumulative survival rate. Results The technical success rate of TIPS was 82.6%. There were significant differences in 6-, 12-, and 24-month cumulative rebleeding-free rates between the TIPS success group and the TIPS failure group (94.3%/89.8%/89.8% vs 85.7%/85.7%/28.6%, χ²=4.563, P=0.033). In the TIPS success group, the 6-, 12-, and 24-month cumulative stent patency rates were 79.3%, 74.3%, and 69.0%, respectively, and the 6-, 12-, and 24-month cumulative HE-free rates after TIPS were 72.1%, 55.5%, and 55.5%, respectively. There were significant differences in 6-, 12-, and 24-month cumulative survival rates between the TIPS success group and the TIPS failure group (94.0%/94.0%/86.2% vs 71.4%/71.4%/71.4%, χ²=4.988, P=0.026). Conclusion TIPS is a safe and feasible method for preventing esophageal variceal rebleeding in patients with PVT after splenectomy, and TIPS combined with a percutaneous transhepatic approach may promote technical success.
- Portosystemic Shunt, Transjugular Intrahepatic,
- Portal Vein Thrombosis,
- Splenectomy,
- Esophageal and Gastric Varices

FullText(HTML)

References(21)

References

[1]	LUO J, LI M, ZHANG Y, et al. Percutaneous transhepatic intrahepatic portosystemic shunt for variceal bleeding with chronic portal vein occlusion after splenectomy[J]. Eur Radiol, 2018, 28(9): 3661-3668. DOI: 10.1007/s00330-018-5360-z.
[2]	MAKDISSI FF, HERMAN P, MACHADO MA, et al. Portal vein thrombosis after esophagogastric devascularization and splenectomy in schistosomal portal hypertension patients: What's the real importance?[J]. Arq Gastroenterol, 2009, 46(1): 50-56. DOI: 10.1590/s0004-28032009000100014.
[3]	DANNO K, IKEDA M, SEKIMOTO M, et al. Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy[J]. Surgery, 2009, 145(5): 457-464; discussion 465-466. DOI: 10.1016/j.surg.2008.06.030.
[4]	IKEDA M, SEKIMOTO M, TAKIGUCHI S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: A prospective study with contrast-enhanced CT scan[J]. Ann Surg, 2005, 241(2): 208-216. DOI: 10.1097/01.sla.0000151794.28392.a6.
[5]	HE S, HE F. Predictive model of portal venous system thrombosis in cirrhotic portal hypertensive patients after splenectomy[J]. Int J Clin Exp Med, 2015, 8(3): 4236-4242.
[6]	DIAO YP, YANG N, GUO LL, et al. Unconventional interventional therapy for cavernous transformation of the portal vein[J]. Ann Vasc Surg, 2014, 28(7): 1791. e9-1791. e11. DOI: 10.1016/j.avsg.2014.03.005.
[7]	SENZOLO M, TIBBALS J, CHOLONGITAS E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation[J]. Aliment Pharmacol Ther, 2006, 23(6): 767-775. DOI: 10.1111/j.1365-2036.2006.02820.x.
[8]	LUCA A, MIRAGLIA R, CARUSO S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis[J]. Gut, 2011, 60(6): 846-852. DOI: 10.1136/gut.2010.228023.
[9]	RADOSEVICH PM, RING EJ, LABERGE JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion[J]. Radiology, 1993, 186(2): 523-527. DOI: 10.1148/radiology.186.2.8421759.
[10]	LUO X, WANG Z, TSAUO J, et al. Advanced cirrhosis combined with portal vein thrombosis: A randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding[J]. Radiology, 2015, 276(1): 286-293. DOI: 10.1148/radiol.15141252.
[11]	FANELLI F, ANGELONI S, SALVATORI FM, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma[J]. Dig Liver Dis, 2011, 43(1): 78-84. DOI: 10.1016/j.dld.2010.06.001.
[12]	QI X, HAN G, YE C, et al. Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients[J]. Med Sci Monit, 2016, 22: 2528-2550. DOI: 10.12659/msm.898866.
[13]	WANG MQ, LIN HY, GUO LP, et al. Acute extensive portal and mesenteric venous thrombosis after splenectomy: Treated by interventional thrombolysis with transjugular approach[J]. World J Gastroenterol, 2009, 15(24): 3038-3045. DOI: 10.3748/wjg.15.3038.
[14]	QI X, BAI M, GUO X, et al. Pharmacologic prophylaxis of portal venous system thrombosis after splenectomy: A meta-analysis[J]. Gastroenterol Res Pract, 2014, 2014: 292689. DOI: 10.1155/2014/292689.
[15]	SONG B, MIN P, OUDKERK M, et al. Cavernous transformation of the portal vein secondary to tumor thrombosis of hepatocellular carcinoma: Spiral CT visualization of the collateral vessels[J]. Abdom Imaging, 2000, 25(4): 385-393. DOI: 10.1007/s002610000057.
[16]	KINJO N, KAWANAKA H, AKAHOSHI T, et al. Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension[J]. Br J Surg, 2010, 97(6): 910-916. DOI: 10.1002/bjs.7002.
[17]	LUO X, NIE L, ZHOU B, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma[J]. Gastroenterol Res Pract, 2014, 2014: 659726. DOI: 10.1155/2014/659726.
[18]	HAN G, QI X, HE C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis[J]. J Hepatol, 2011, 54(1): 78-88. DOI: 10.1016/j.jhep.2010.06.029.
[19]	DONG F, LUO SH, ZHENG LJ, et al. Incidence of portal vein thrombosis after splenectomy and its influence on transjugular intrahepatic portosystemic shunt stent patency[J]. World J Clin Cases, 2019, 7(17): 2450-2462. DOI: 10.12998/wjcc.v7.i17.2450.
[20]	WANG L, HE F, YUE Z, et al. Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein[J]. Sci Rep, 2017, 7(1): 10868. DOI: 10.1038/s41598-017-11455-y.
[21]	STAMOU KM, TOUTOUZAS KG, KEKIS PB, et al. Prospective study of the incidence and risk factors of postsplenectomy thrombosis of the portal, mesenteric, and splenic veins[J]. Arch Surg, 2006, 141(7): 663-669. DOI: 10.1001/archsurg.141.7.663.

Relative Articles

[1]	Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810
[2]	Xiaoyong DUO, Shijie ZHANG, Hongwei ZHANG, Jing YANG, Wenqiang WANG, Linzhi YU, Baocai ZHANG, Yicheng ZHUO, Yunchao JIA, Yan PENG, Shuai HU. Association between gallstones and metabolic syndrome in southern Xinjiang, China[J]. Journal of Clinical Hepatology, 2022, 38(8): 1859-1864. doi: 10.3969/j.issn.1001-5256.2022.08.026
[3]	CHEN Huan, LI Ting, WANG ZiJie, WANG ZhongQiong, LUO Gang, DENG MingMing. Influence of metabolic syndrome and its components on the prognosis of patients with pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(12): 2788-2794. doi: 10.3969/j.issn.1001-5256.2020.12.029
[4]	Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024
[5]	Niu ChunYan, Liu Qin, Luo XiaoChun. Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression[J]. Journal of Clinical Hepatology, 2020, 36(10): 2356-2359. doi: 10.3969/j.issn.1001-5256.2020.10.043
[6]	Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010
[7]	Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013
[8]	Zhou BingBing, Wang XueMei, Zhang Qian, Xu ShiYi, Dan ZhongYan, Lai YaXin, Wang HaoYu. Association between metabolic syndrome and gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 880-882. doi: 10.3969/j.issn.1001-5256.2017.05.017
[9]	Xu BeiBei, Wang BingYuan. Nonalcoholic fatty liver disease and serum uric acid[J]. Journal of Clinical Hepatology, 2016, 32(3): 437-441. doi: 10.3969/j.issn.1001-5256.2016.03.007
[10]	Li LiangPing. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 432-436. doi: 10.3969/j.issn.1001-5256.2016.03.006
[11]	Fan JianGao, Yan ShiYan. Metabolic syndrome and fatty liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 407-410. doi: 10.3969/j.issn.1001-5256.2016.03.001
[12]	Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016
[13]	Huang Ying, Chen Hong. Research progress in association between nonalcoholic fatty liver disease and gallstone disease[J]. Journal of Clinical Hepatology, 2014, 30(11): 1217-1220. doi: 10.3969/j.issn.1001-5256.2014.11.033
[14]	Fan JianGao, Zhu ChanYan. Strengthening research on relationship between metabolic syndrome and chronic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 881-884. doi: 10.3969/j.issn.1001-5256.2013.12.001
[15]	Yan Jie, Xie Wen. Relationship between metabolic syndrome and chronic hepatitis C[J]. Journal of Clinical Hepatology, 2013, 29(12): 887-889. doi: 10.3969/j.issn.1001-5256.2013.12.003
[16]	Li LiangPing, Zhong Huang. The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 359-363.
[17]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.
[18]	Wu Tao, Yin ShouYi, Wang HongZhang, Zhang Hong, Jia Wei, Ji Guang. The clinical features and risk factors of patient with metabolic syndrome combined with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1036-1040.
[19]	Ruan JianWen, Yang Jing, Gao LiJuan. Advances in the relationship between metabolic syndrome and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1102-1105.
[20]	Niu ChunYan, Yan Rong, Tian Yu, Ma HuiXia, Jiao ShuJiang. The prevalence of fatty liver disease and its relationship with metabolic syndrome[J]. Journal of Clinical Hepatology, 2010, 26(2): 167-169.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	梁海锋，梁国志，袁观斗，郭振亚，何松青. 小肝综合征的发病机制及防治研究进展. 中华实验外科杂志. 2024(03): 639-643 .
2.	蔡景治，郑扬，仲伟明，刘波. 基于Bcl-2/CytC探究槲皮素对肝硬化大鼠微循环及肝脏病变的影响. 现代生物医学进展. 2023(05): 818-823 .
3.	赵媛，赵明，范玉梅，邵建营. 失代偿期乙型肝炎肝硬化患者不同病毒学应答状态对生存率及肝癌患病率的影响. 中国实用医刊. 2020(23): 50-52 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (632) PDF downloads(34)

Value of transjugular intrahepatic portosystemic shunt in the prevention of esophageal variceal rebleeding in patients with portal vein thrombosis after splenectomy

DOI: 10.3969/j.issn.1001-5256.2021.06.023